CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2018	[1]	Sep. 30, 2017	Sep. 30, 2018	[1]	Sep. 30, 2017
Revenues [Abstract]
Revenues	$ 1,566,425		$ 1,549,016	$ 5,790,302		$ 4,607,162
Cost of goods sold	115,907		230,049	484,801		568,071
Gross profit	1,450,518		1,318,967	5,305,501		4,039,091
Operating expenses
Selling, general and administrative expense	1,561,197		1,303,344	5,263,858		3,799,644
Depreciation and amortization	21,316		41,400	63,392		82,329
Bad debt expense	0		2,998	12,558		8,913
Total operating expenses	1,582,513		1,347,742	5,339,808		3,890,886
Operating income / (loss)	(131,995)		(28,775)	(34,307)		148,205
Other income / (expense)
Income from equity method investment - Cellerate, LLC	10,906		0	10,906		0
Change in fair value of derivative liability	0		6	0		44
Other expense / (income)	(22,957)		14	(22,655)		65
Interest Expense	(6,986)		(19,807)	(67,594)		(115,421)
Debt Forgiveness	0		0	0		50,646
Total other income (expense)	(19,037)		(19,787)	(79,343)		(64,666)
Net income / (loss)	(151,032)		(48,562)	(113,650)		83,539
Series C preferred stock dividends	0		(42,873)	(28,061)		(100,677)
Series C Preferred Stock inducement dividends	0		0	(103,197)		0
Net loss available to common shareholders	$ (151,032)		$ (91,435)	$ (244,908)		$ (17,138)
Basic loss per share of common stock	$ (0.00)		$ (0.00)	$ (0.00)		$ (0.00)
Diluted loss per share of common stock	$ (0.00)		$ (0.00)	$ (0.00)		$ (0.00)
Weighted average number of common shares outstanding basic	236,642,901		111,161,335	210,599,065		110,536,584
Weighted average number of common shares outstanding diluted	236,642,901		111,161,335	210,599,065		110,536,584

[1] See Note 1, Principles of Consolidation for more information regarding the use of the equity method of accounting beginning September 1, 2018.